Department of Pharmacy, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj, 8100, Bangladesh; BioLuster Research Center Ltd., Gopalgaj (Dhaka), 8100, Bangladesh.
Department of Pharmacy, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj, 8100, Bangladesh.
Comput Biol Med. 2024 Dec;183:109298. doi: 10.1016/j.compbiomed.2024.109298. Epub 2024 Oct 24.
The present work is designed to explore the anti-inflammatory properties of AA and its modulatory effects on celecoxib (CEL) and ketoprofen (KET) through in vitro, ex vivo, in vivo, and in silico approaches. Different concentrations of AA were utilized to evaluate the membrane-stabilizing potential via egg albumin and the Human Red Blood Cell (HRBC) denaturation model. In the animal model, formalin (50 μL) was injected into the right hind paw of young chicks to induce inflammation. AA was administered at 20 and 40 mg/kg (p.o.) to the experimental animals. We used CEL and KET as positive controls. The vehicle was provided as a control group. Two combinations of AA with CEL and KET were also investigated in all tests to assess the modulatory activity of AA. In addition, in silico investigation was used for predictions about drug-likeness, pharmacokinetics, and toxicity of the selected chemical compounds, and the study also evaluated the binding affinity, visualization, and stability of ligand-receptor interactions through molecular dynamic (MD) simulation. Results manifested that AA concentration-dependently significantly inhibited the egg albumin denaturation (IC: 27.53 ± 0.88 μg/ml) and breakdown of HRBC (IC: 15.69 ± 0.75 μg/ml), indicating the membrane stabilizing potential compared to the control group. AA also significantly (p < 0.05) lessened the frequency of licking and alleviated the paw edema in a dose-dependent manner in an in vivo test. However, AA reduced the activity of CEL and KET in combination treatment. AA showed good pharmacokinetic characteristics to be considered as a therapeutic candidate. Additionally, the in silico study displayed that AA demonstrated a relatively higher docking score of -9.1 kcal/mol with the cyclooxygenase-2 (COX-2) enzyme and stable binding in MD simulation. Whereas the standard ligand (CEL) expressed the highest binding value of -9.2 kcal/mol to the COX-2.
本研究旨在通过体外、离体、体内和计算方法探索 AA 的抗炎特性及其对塞来昔布(CEL)和酮洛芬(KET)的调节作用。通过卵白蛋白和人红细胞(HRBC)变性模型,利用不同浓度的 AA 来评估其膜稳定潜力。在动物模型中,向小鸡的右后爪注射 50 μL 甲醛以诱导炎症。AA 以 20 和 40 mg/kg(po)的剂量给予实验动物。我们使用 CEL 和 KET 作为阳性对照。给予载体作为对照组。还在所有测试中研究了 AA 与 CEL 和 KET 的两种组合,以评估 AA 的调节活性。此外,还进行了计算研究,以预测所选化学化合物的类药性、药代动力学和毒性,该研究还通过分子动力学(MD)模拟评估了配体-受体相互作用的结合亲和力、可视化和稳定性。结果表明,AA 浓度依赖性地显著抑制卵白蛋白变性(IC:27.53±0.88 μg/ml)和 HRBC 破裂(IC:15.69±0.75 μg/ml),与对照组相比具有膜稳定潜力。AA 还显著(p<0.05)减少了舔舐的频率,并以剂量依赖性方式减轻了爪水肿。然而,AA 降低了联合治疗中 CEL 和 KET 的活性。AA 表现出良好的药代动力学特征,可被视为治疗候选药物。此外,计算研究显示,AA 与环氧化酶-2(COX-2)酶的对接评分相对较高,为-9.1 kcal/mol,在 MD 模拟中具有稳定的结合。而标准配体(CEL)与 COX-2 的结合值最高为-9.2 kcal/mol。